Mankind Pharma has released the pledge on 28,280 equity shares of Bharat Serums and Vaccines Limited (BSVL), representing 38.68% of BSVL’s paid-up equity share capital, following the creation of a revised security cover for its outstanding non-convertible debentures (NCDs).

The development comes in continuation of the company’s May 19, 2026 intimation to the stock exchanges, in which Mankind Pharma had informed about the Board’s approval for realignment of the security cover for its existing NCDs bearing ISINs INE634S07025 and INE634S07033.

Mankind Pharma said the revised security was created in favour of Catalyst Trusteeship Limited, the debenture trustee, over tangible and intangible assets of the company and its subsidiaries after receiving the requisite approvals from NCD holders and BSE Limited on July 13 and July 21, 2026, respectively.

Following the creation of the revised security, the pledge on the 28,280 BSVL shares, which had been maintained in favour of the debenture trustee on behalf of NCD holders, was released on August 17, 2026.

The company said the revised security cover currently stands at 1.26 times the outstanding NCD amount, in compliance with applicable SEBI regulations and the terms of the Debenture Trust Deeds.

With the release of the pledge, no shares of Bharat Serums and Vaccines are now pledged as security for Mankind Pharma’s NCDs.